Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1

被引:7
|
作者
Mur, Pilar [1 ,2 ,3 ,4 ]
Viana-Errasti, Julen [1 ,2 ]
Garcia-Mulero, Sandra [4 ,5 ]
Magraner-Pardo, Lorena [6 ,7 ]
Munoz, Ines G. [8 ]
Pons, Tirso [9 ]
Capella, Gabriel [1 ,2 ,3 ]
Pineda, Marta [1 ,2 ,3 ]
Feliubadalo, Lidia [1 ,2 ,3 ]
Valle, Laura [1 ,2 ,3 ]
机构
[1] Catalan Inst Oncol, IDIBELL, Hereditary Canc Program, Barcelona, Spain
[2] IDIBELL, Program Mol Mech & Expt Therapy Oncol Oncobell, Barcelona, Spain
[3] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[4] Catalan Canc Plan, Dept Hlth Catalonia, Barcelona, Spain
[5] Catalan Inst Oncol, Oncol Data Analyt Program ODAP, Unit Biomarkers & Susceptibil, Barcelona, Spain
[6] Inst Canc Res ICR, CRUK Gene Funct Lab, London, England
[7] Inst Canc Res ICR, Breast Canc Now Toby Robins Res Ctr, London, England
[8] Spanish Natl Canc Res Ctr CNIO, Struct Biol Program, Prot Crystallog Unit, Madrid, Spain
[9] Spanish Natl Res Council, Natl Ctr Biotechnol CNB CSIC, Dept Immunol & Oncol, Madrid, Spain
关键词
Polymerase proofreading-associated polyposis; PPAP; Polymerase epsilon; Polymerase delta; Proofreading deficiency; Mutational signatures; Variant classification; Hereditary cancer; DNA-POLYMERASE EPSILON; MICROSATELLITE INSTABILITY; MUTATIONS; CRITERIA; COLON; PATHOGENICITY; GUIDELINES; SIGNATURES; BLOCKADE; FEATURES;
D O I
10.1186/s13073-023-01234-y
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
BackgroundGermline variants affecting the proofreading activity of polymerases epsilon and delta cause a hereditary cancer and adenomatous polyposis syndrome characterized by tumors with a high mutational burden and a specific mutational spectrum. In addition to the implementation of multiple pieces of evidence for the classification of gene variants, POLE and POLD1 variant classification is particularly challenging given that non-disruptive variants affecting the proofreading activity of the corresponding polymerase are the ones associated with cancer. In response to an evident need in the field, we have developed gene-specific variant classification recommendations, based on the ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology) criteria, for the assessment of non-disruptive variants located in the sequence coding for the exonuclease domain of the polymerases.MethodsA training set of 23 variants considered pathogenic or benign was used to define the usability and strength of the ACMG/AMP criteria. Population frequencies, computational predictions, co-segregation data, phenotypic and tumor data, and functional results, among other features, were considered.ResultsGene-specific variant classification recommendations for non-disruptive variants located in the exonuclease domain of POLE and POLD1 were defined. The resulting recommendations were applied to 128 exonuclease domain variants reported in the literature and/or public databases. A total of 17 variants were classified as pathogenic or likely pathogenic, and 17 as benign or likely benign.ConclusionsOur recommendations, with room for improvement in the coming years as more information become available on carrier families, tumor molecular characteristics and functional assays, are intended to serve the clinical and scientific communities and help improve diagnostic performance, avoiding variant misclassifications.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Molecular and clinical characteristics of POLE/POLD1 alterations among patients with colorectal cancer
    Syed, Masood Pasha
    Ferrell, Morgan
    Cheng, Svea
    Gonzalez, Cyndi
    Giza, Richard
    Magge, Tara
    Bao, Riyue
    Singhi, Aatur D.
    Saeed, Anwaar
    Sahin, Ibrahim Halil
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 184 - 184
  • [42] POLE and POLD1 Variant Detection: Potential Immune-Checkpoint Inhibitor Biomarker
    Besharati, Sepideh
    Fazlollahi, Ladan
    Remotti, Helen
    MODERN PATHOLOGY, 2022, 35 : 491 - 491
  • [43] Race, Prevalence of POLE and POLD1 Alterations, and Survival Among Patients With Endometrial Cancer
    Zheng, Shuhua
    Donnelly, Eric D.
    Strauss, Jonathan B.
    JAMA NETWORK OPEN, 2024, 7 (01) : E2351906
  • [44] Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1
    Buchanan, Daniel D.
    Stewart, Jenna R.
    Clendenning, Mark
    Rosty, Christophe
    Mahmood, Khalid
    Pope, Bernard J.
    Jenkins, Mark A.
    Hopper, John L.
    Southey, Melissa C.
    Macrae, Finlay A.
    Winship, Ingrid M.
    Win, Aung Ko
    GENETICS IN MEDICINE, 2018, 20 (08) : 890 - 895
  • [45] POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance
    Bellido, Fernando
    Pineda, Marta
    Aiza, Gemma
    Valdes-Mas, Rafael
    Navarro, Matilde
    Puente, Diana A.
    Pons, Tirso
    Gonzalez, Sara
    Iglesias, Silvia
    Darder, Esther
    Pinol, Virginia
    Luis Soto, Jose
    Valencia, Alfonso
    Blanco, Ignacio
    Urioste, Miguel
    Brunet, Joan
    Lazaro, Conxi
    Capella, Gabriel
    Puente, Xose S.
    Valle, Laura
    GENETICS IN MEDICINE, 2016, 18 (04) : 325 - 332
  • [46] POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes
    Luigi Magrin
    Daniele Fanale
    Chiara Brando
    Alessia Fiorino
    Lidia Rita Corsini
    Roberta Sciacchitano
    Clarissa Filorizzo
    Alessandra Dimino
    Antonio Russo
    Viviana Bazan
    Oncogene, 2021, 40 : 5893 - 5901
  • [47] Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity
    Ma, Xiaoxiao
    Riaz, Nadeem
    Samstein, Robert M.
    Lee, Mark
    Makarov, Vladimir
    Valero, Cristina
    Chowell, Diego
    Kuo, Fengshen
    Hoen, Douglas
    Fitzgerald, Conall W. R.
    Jiang, Hui
    Alektiar, Jonathan
    Alban, Tyler J.
    Juric, Ivan
    Parthasarathy, Prerana Bangalore
    Zhao, Yu
    Sabio, Erich Y.
    Verma, Richa
    Srivastava, Raghvendra M.
    Vuong, Lynda
    Yang, Wei
    Zhang, Xiao
    Wang, Jingming
    Chu, Lawrence K.
    Wang, Stephen L.
    Kelly, Daniel W.
    Pei, Xin
    Chen, Jiapeng
    Yaeger, Rona
    Zamarin, Dmitriy
    Zehir, Ahmet
    Gonen, Mithat
    Morris, Luc G. T.
    Chan, Timothy A.
    NATURE GENETICS, 2022, 54 (07) : 996 - +
  • [48] POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes
    Magrin, Luigi
    Fanale, Daniele
    Brando, Chiara
    Fiorino, Alessia
    Corsini, Lidia Rita
    Sciacchitano, Roberta
    Filorizzo, Clarissa
    Dimino, Alessandra
    Russo, Antonio
    Bazan, Viviana
    ONCOGENE, 2021, 40 (40) : 5893 - 5901
  • [49] Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity
    Xiaoxiao Ma
    Nadeem Riaz
    Robert M. Samstein
    Mark Lee
    Vladimir Makarov
    Cristina Valero
    Diego Chowell
    Fengshen Kuo
    Douglas Hoen
    Conall W. R. Fitzgerald
    Hui Jiang
    Jonathan Alektiar
    Tyler J. Alban
    Ivan Juric
    Prerana Bangalore Parthasarathy
    Yu Zhao
    Erich Y. Sabio
    Richa Verma
    Raghvendra M. Srivastava
    Lynda Vuong
    Wei Yang
    Xiao Zhang
    Jingming Wang
    Lawrence K. Chu
    Stephen L. Wang
    Daniel W. Kelly
    Xin Pei
    Jiapeng Chen
    Rona Yaeger
    Dmitriy Zamarin
    Ahmet Zehir
    Mithat Gönen
    Luc G. T. Morris
    Timothy A. Chan
    Nature Genetics, 2022, 54 : 996 - 1012
  • [50] Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
    Ambrosini, M.
    Rousseau, B.
    Manca, P.
    Artz, O.
    Marabelle, A.
    Andre, T.
    Maddalena, G.
    Mazzoli, G.
    Intini, R.
    Cohen, R.
    Cercek, A.
    Segal, N. H.
    Saltz, L.
    Varghese, A. M.
    Yaeger, R.
    Nusrat, M.
    Goldberg, Z.
    Ku, G. Y.
    El Dika, I.
    Margalit, O.
    Grinshpun, A.
    Kasi, P. Murtaza
    Schilsky, R.
    Lutfi, A.
    Shacham-Shmueli, E.
    Afghan, M. Khan
    Weiss, L.
    Westphalen, C. B.
    Conca, V.
    Decker, B.
    Randon, G.
    Elez, E.
    Fakih, M.
    Schrock, A. B.
    Cremolini, C.
    Jayachandran, P.
    Overman, M. J.
    Lonardi, S.
    Pietrantonio, F.
    ANNALS OF ONCOLOGY, 2024, 35 (07) : 643 - 655